[Medical oncology trends].
The 2007 vintage leads to renewed enthusiasm in medical oncology, as published data with major impact on daily practice relate to many areas. While we do not review congress abstracts, exceptions are needed to this rule. Indeed, after renal cell cancer patients, we now see patients with another tumor, difficult to treat so far, being offered some hope: hepatocarcinoma has been the focus of recent attention. While many of the reviewed papers are about "targeted" cancer treatment, progress in chemotherapy data is also remarkable. One simply continues to regret the lack of focused studies which would improve on the response rates and survival impact. One may hope that the near future will deliver on this, leading to an increased treatment effectiveness and decreased exposure to unjustified toxicity.
Aapro
M S
MS
Institut multidisciplinaire d'oncologie, Clinique de Genolier, 1272 Genolier. maapro@genolier.net
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000628:therapy*; D011379:Prognosis
D000970:Antineoplastic Agents